This trial is active, not recruiting.

Condition myasthenia gravis
Treatments methotrexate, placebo
Phase phase 2
Sponsor University of Kansas
Start date April 2009
End date April 2014
Trial size 50 participants
Trial identifier NCT00814138, 11552, FDA OOPD 003538


Myasthenia gravis is a rare neuromuscular disorder characterized by weakness and fatigability of ocular, bulbar, and extremity musculature. The specific aim of this study is to determine if oral methotrexate is an effective therapy for myasthenia gravis (MG) patients who are prednisone dependent. Patients will be randomized to receive either methotrexate or placebo and those who are entered onto this trial will have symptoms and signs of the disease while on prednisone therapy. The hypothesis is that adding methotrexate therapy in these patients will improve the MG manifestations so that the prednisone dose can be reduced and clinical measures of MG severity will improve.

Funding Source - FDA OOPD

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, investigator)
Primary purpose treatment
(Active Comparator)
10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study
(Placebo Comparator)

Primary Outcomes

Total prednisone dose
time frame: 9 months

Secondary Outcomes

Quantitative Myasthenia Gravis score
time frame: baseline, monthly for 12 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patients must have MGFA MG grades 2, 3, or 4 generalized myasthenia gravis, according to the MGFA classification system - Elevated acetylcholine receptor antibody (AChR-Ab) titer. - Patient's signs and symptoms should not be better explained by another disease process. - Prednisone dose of at least 10 mg/day (or the equivalent in alternate days) and the subject must be on a stable dose of prednisone for 30 days prior to the screening visit. Exclusion Criteria: - A history of chronic degenerative, psychiatric, or neurologic disorder other than MG that can produce weakness or fatigue. - Other major chronic or debilitating illnesses within six months prior to study entry. - Female patients who are premenopausal and are: (a) pregnant on the basis of a serum pregnancy test, (b) breast-feeding, or (c) not using an effective method of double barrier (1 hormonal plus 1 barrier method or 2 simultaneous barrier methods) birth control (birth control pills, male condom, female condom, intrauterine device, Norplant, tubal ligation, or other sterilization procedures). - Altered levels of consciousness, dementia, or abnormal mental status. - Evidence of thymoma on chest CT or MRI. Such a finding could require immediate thymectomy and would preclude entry into the study. - Thymectomy in the previous three months. - Patients who have been medicated with azathioprine, cyclosporine, cyclophosphamide, mycophenolate mofetil, IVIg, or other immunosuppressive drugs within the last 60 days. - Chest X-ray with evidence of tumor, infection, or interstitial lung disease. - Clinical history of chronic or recurrent infections. - Daily use of non-steroidal anti-inflammatory drugs (NSAIDs). - History of renal or hepatic insufficiency or liver enzymes greater than the upper limit of normal. - History of bone marrow hypoplasia, leucopenia, thrombocytopenia, significant anemia, clinical or laboratory evidence of immunodeficiency syndromes. - Forced Vital Capacity (FVC) <50% of predicted. - MG Grade 1 (ocular only) or 5 (crisis, requiring ventilator). - Prior use of methotrexate for any condition.

Additional Information

Official title Phase II Trial of Methotrexate in Myasthenia Gravis
Principal investigator Richard Barohn, MD
Trial information was received from ClinicalTrials.gov and was last updated in February 2014.
Information provided to ClinicalTrials.gov by University of Kansas.